NCT Number: NCT04946370
Phase: Phase 1|Phase 2
Trial Summary: This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that i – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym:
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives